Resultat 1 - 4 av 4
Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses
Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closedSammanhang: ...Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. ...
Omnämnda personer: Peritoneal Carcinomatoses Oncoinvent ASA.
Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients
Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient has been dosed in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarianSammanhang: ...Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient has been dosed in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer. Radspherin® is a novel alpha-radiation therapy candidate designed for targeted, local treatment of cancers that have spread to body cavities. ...
Omnämnda personer: with Radspherin.
ZINZINO AB (PUBL.): ZINZINO FÖRVÄRVAR 49% AV CYPRIOTISKA OLIVOLJEPRODUCENTEN CLEANTHI ALPHA-OLENIC LTD
Sammanhang: ....): ZINZINO FÖRVÄRVAR 49% AV CYPRIOTISKA OLIVOLJEPRODUCENTEN CLEANTHI ALPHA-OLENIC LTD...
Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer
Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast TrackSammanhang: ...FDA Fast Track Designation accelerates the approval process for Alpha 1H and potential for reaching the US market....
Omnämnda platser: Lund, Sweden. Omnämnda personer: Hamlet BioPharma, Hamlet BioPharma AB.